[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frontotemporal-dementia-behavioral-variant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frontotemporal-dementia-behavioral-variant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,82,116,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633826","links-between-self-awareness-and-sociocognitive-processes-in-neurodegenerative-diseases-100633826",false,"NCT07531732","Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases","Study of the Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases in People With Frontotemporal Lobar Degeneration, Behavioral Variant and Alzheimer's Disease","SELFSOC","Inclusion Criteria:\n\n* Diagnosis of possible or probable behavioral variant frontotemporal dementia according to the Rascovsky 2011 criteria (DLFTvc group) OR\n* Diagnosis of Alzheimer's disease according to the Jack 2018 criteria, including biomarkers (MA group)\n* Mini-Mental State Examination (MMSE) ≥ 20\n* Age: 50-80 years\n* Sufficient reading and writing proficiency in French to enable completion of the study procedures, in the investigator's opinion\n\nExclusion Criteria:\n\n* Moderate to severe language disorders: Confrontation naming (DO 40 scale) ≤ 32\n* Inability to perform computerized tasks according to the investigator's opinion\n* Other neurological disorders (including epilepsy, Lewy body disease, vascular dementia)\n* Psychiatric comorbidities (bipolar disorder, schizophrenia, current major depressive episode)\n* Uncorrected visual impairment","ALL","50 Years","80 Years",{"count":21,"type":22},34,"ESTIMATED","OBSERVATIONAL","This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).\n\nThe primary objective is to assess metacognitive efficiency related to social cognitive performance using a computerized facial emotion recognition task combined with confidence judgments. Metacognitive indices (including Mratio) will quantify the correspondence between subjective and objective performance.\n\nThirty-four participants (17 bvFTD, 17 AD; age 50-80; MMSE ≥20) will complete two study visits involving tasks assessing emotion recognition, theory of mind, and memory.",[26,27],"Frontotemporal Dementia, Behavioral Variant","Alzheimer Disease",[29,30,31,32,33,34],"Metacognition","Social cognition","Emotion recognition","Theory of Mind","Neuropsychology","Hypnotic suggestibility","RECRUITING","2026-04-08",{"date":38,"type":39},"2026-04-15","ACTUAL",{"date":41,"type":22},"2026-04",{"date":43,"type":22},"2027-12",{"name":45,"class":46},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100562542","phase-2-vortioxetine-for-the-treatment-of-mood-and-cognitive-symptoms-in-frontotemporal-dementia-100562542","NCT06604520","Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia","Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia","FTD Patients\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)\n4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation\n5. A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one\n6. Patients must be medically stable\n7. Vortioxetine treatment is clinically indicated\n8. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No history of drug or alcohol dependence within six months prior to study entry\n2. Negative toxicology screening for drugs of abuse\n3. Subject must not be pregnant or nursing\n4. No contraindications to Vortioxetine treatment\n5. No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)\n\nHealthy Controls\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Subjects must be medically stable\n4. Free of psychotropic medications\n5. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No current or past history of neurological or psychiatric illness or substance abuse\n2. Subject must not be pregnant or nursing\n3. Negative toxicology screening for drugs of abuse\n4. No contraindications for MR scanning (e.g. metal implanted in the body)",true,"45 Years",{"count":58,"type":22},50,"INTERVENTIONAL",[61],"PHASE2","The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:\n\n1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?\n2. Do mood symptoms and cognition improve following treatment with vortioxetine?\n\nResearchers will also determine whether there are changes in the brain associated with vortioxetine treatment.\n\nParticipants will:\n\n* Undergo a screening visit that involves clinical assessments and laboratory tests\n* Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine\n* Undergo memory and problem-solving tests before starting treatment with vortioxetine\n* Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist\n* Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine",[64,65,66,67,26,68],"Fronto-temporal Dementia","Fronto-temporal Lobar Dementia","Frontotemporal Degeneration","Frontotemporal Dementia (FTD)","Frontotemporal Dementia",[70,68,71,72],"FTD","Neuropsychiatric Symptoms","Antidepressant","2026-03-05",{"date":75,"type":39},"2026-03-09",{"date":77,"type":39},"2025-03-20",{"date":79,"type":22},"2029-09-01",{"name":81,"class":46},"Johns Hopkins University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":59,"phases":93,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100496320","phase-2-nabilone-for-agitation-in-frontotemporal-dementia-100496320","NCT05742698","Nabilone for Agitation in Frontotemporal Dementia","Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia","Nabilone-FTD","Inclusion Criteria:\n\n* Men and women over 18 years\n* Major neurocognitive disorder due to probable behavioural variant FTD (Rascovsky criteria)17 or primary progressive aphasia (Gorno-Tempini criteria)18. All ages and severity levels will be included.\n* Meets International Psychogeriatric Association criteria for agitation in cognitive disorders19\n* CMAI score of 39 or above\n* Stable psychoactive medication for 2 weeks prior to screening (all medications allowed) with no intention to change dose during treatment period\n* Available study partner with ≥10 hours per week in-person contact with the patient. This can either be a friend\u002Ffamily member or a staff member at an assisted living facility.\n* Capacity to provide written consent in English or French, or consent from official surrogate decision maker in case of incapacity\n\nRationale for Inclusion Criteria: The inclusion criteria are designed to enroll patients with FTD with the behaviours of interest, with a range of disease severity that will permit assessment of all outcome measures.\n\nExclusion Criteria:\n\n* Clinically significant psychotic symptoms (Neuropsychiatric Inventory domain score (severity x frequency) ≥4 on the delusions or hallucinations subscale)\n* Clinically significant orthostatic hypotension (a decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within three minutes of standing compared to blood pressure in a seated position)\n* Symptomatic orthostatic tachycardia (heart rate increase from of at least 30 beats per minute within the first 5 minutes of standing compared to a seated position IF orthostatic hypotension is not a problem)\n* Unstable cardiovascular condition in the opinion of the investigator\n* Known or suspected history of drug or alcohol dependence or abuse in the past 12 months, including use of any psychomimetic drugs (e.g. ketamine, lysergic acid diethylamide, psilocybin).\n* Allergy, or significant adverse reaction to cannabinoids. If the adverse reaction involved psychological symptoms that are indicative of psychosis or severe anxiety the patient will be excluded. Their treating clinician may be consulted for a clinical opinion on the severity of the response to cannabis and whether this justifies exclusion from the trial.\n* Major depressive episode within 6 months of screening\n* Women who are breast feeding or pregnant\n* Severe liver dysfunction, as determined by their treating clinician\n* Other psychiatric or neurological condition that could cause significant agitation\n* Ongoing use of any cannabinoid-related products. This includes any THC or CBD based products, regardless of administration method (oral, inhalation, topical, etc…)\n\nRationale for Exclusion Criteria: The exclusion criteria are designed to avoid inclusion of patients who may have medical comorbidities that would increase their risk of serious side effects from repeated nabilone administration.","18 Years",{"count":92,"type":22},45,[61],"The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.",[68,26,96,97,98,70],"Primary Progressive Aphasia","bvFTD","PPA",[100,101,102,103,104,105,70],"Nabilone","Nabilone FTD","Agitation","TEVA Nabilone","Dementia","BvFTD","2025-04-11",{"date":108,"type":39},"2025-04-15",{"date":110,"type":39},"2023-03-07",{"date":112,"type":22},"2026-05",{"name":114,"class":46},"Simon Ducharme, MD",7,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":55,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":59,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":47},"100570395","a-study-of-the-behavioral-variant-of-frontotemporal-dementia-and-bipolar-disorder-a-neuroimaging-and-epigenetics-integrated-approach-100570395","NCT06706687","A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated Approach","DISBAND","Inclusion Criteria:\n\n* byFTD group: patients of either sex; 18 years of age or older; diagnosis of behavioral variant Frontotemporal Dementia according to current diagnostic criteria; presence of a signed informed consent.\n* BD group: patients of either sex; 18 years of age or older; diagnosis of bipolar disorder according to DSM-V criteria; presence of a signed informed consent.\n* HC group: patients of either sex; 18 years of age or older; subjects who have gone through the same diagnostic process as patients under suspicion of a central nervous system and\u002For psychiatric disorder, resulting in the absence of cognitive deficits and mood disorders; presence of a signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of Alzheimer's disease\n* Comorbidities interfering with the studied condition (e.g. other neurological diseases or history of substance or alcohol abuse)\n* Diseases with an inflammatory component (e.g. autoimmune diseases, tumors)\n* Pregnancy",{"count":124,"type":22},210,[126],"NA","The aim of this study is to investigate the selective epigenetic modifications and their effect on brain's morphology and functionality in the frontotemporal dementia behavioral variant and bipolar disorder. The open-label, multicentric, interventional case-control study involves the analysis of 3 separate cohorts of patients, partly selected over the course of the past 10 years. More specifically, 80 behavioral variant Frontotemporal Dementia (bvFTD) patients (40, of whom 20 carry G4C2 expansion in the C9orf72 gene, are already available, while 40 will be prospectively recruited), 80 Bipolar Disorder (BD) patients (40, including 20 with early onset and 20 with late onset, are already available, while 40 will be prospectively recruited) and 50 healthy control (HC) subjects (20 of whom are already available from other previously approved studies), will be enrolled in this study.\n\nFor each participant a blood sample will be collected, processed, and studied in order analyze the expression of miRNA. Every participant will also undergo Nuclear Magnetic Resonance Imaging (NMR), Nuclear Magnetic Resonance Spectroscopy (1H-MRS), and Positron Emission Tomography (PET) and, lastly, a battery of behavioral scales to explore different cognitive domains will be administered to all participants by a team of psychologists and physicians. The overall estimated duration of the study is 36 months.",[129,26],"Bipolar Disorder",[131,132,133,134,135,136,137,138,139],"Bipolar Disorder (BD)","Frontotemporal Dementia, Behavioral Variant (bvFTD)","Epigenetics","Neuroimaging","miRNA","Nuclear Magnetic Resonance Imaging (NMR)","Nuclear Magnetic Resonance Spectroscopy (1H-MRS)","Positron Emission Tomography (PET)","Healthy controls (HC)","2024-11-22",{"date":142,"type":39},"2024-11-26",{"date":144,"type":39},"2021-05-19",{"date":146,"type":22},"2025-04",{"name":148,"class":46},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":55,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100428908","ecocapture-for-the-assessment-of-apathy-under-real-life-conditions-100428908","NCT04865172","ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions","ECOCAPTURE@HOME: Program for the Assessment of Behavioural Markers of Apathy Under Real-life Conditions Aimed At Patients with Neurodegenerative Dementias and Their Caregivers","@HOME","Inclusion Criteria for patients:\n\n1. Diagnosis of bvFTD according to Rascovsky's international criteria for the bvFTD group \u002F diagnosis of AD according to Dubois's international criteria for the AD group;\n2. No evidence of any other cerebral pathology;\n3. A Mini-Mental State Evaluation (MMSE) score superior or equal to 10 (to minimise the effect of confounding factors related to very severe cognitive impairment);\n4. Aged between 40 and 85;\n5. No evidence of any psychiatric condition and a Montgomery-Åsberg Depression Rating Scale (MADRS) score inferior to 20 (to avoid confusion between depression and apathy);\n6. No evidence of excessive consumption of psychotropic drugs - for instance benzodiazepines, sleeping pills, etc. (due to their tranquilising effect);\n7. No major physical disability disrupting mobility;\n8. No heart pacemaker (which would compromise heart rate measuring).\n\nInclusion Criteria for caregivers and partners of healthy control dyads:\n\n1. Aged between 40 and 85;\n2. No evidence of any psychiatric condition;\n3. A MADRS score inferior to 20;\n4. No evidence of excessive consumption of psychotropic drugs;\n5. No major physical disability disrupting mobility;\n6. No heart pacemaker.\n\nExclusion Criteria:\n\n1. Persons in detention by judicial or administrative decision\n2. Person who is subject to a legal protection order\n3. Person submitted to an exclusion period due to the participation to another research","40 Years","85 Years",{"count":160,"type":22},120,"ECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month. Participants will not only be patients with apathy but also their spouse caregiver. Behavioral markers of apathy will be extracted from a combination of: 1\u002F objective physiological data from sensors on a bracelet worn by participants; 2\u002F subjective data filled by the caregiver through an application. Thus investigators will collect a pool of metrics and show they can measure three assumed behavioral markers of apathy (daytime activity, quality of sleep and emotional arousal), which in turn allow to predict caregiver's perception of the dyad's psychological state. The final goal is to lay the foundations for the development of a clinical tool for the remote follow-up of patient-caregiver couples.",[26,27],"2024-11-19",{"date":165,"type":39},"2024-11-21",{"date":167,"type":39},"2022-05-20",{"date":169,"type":22},"2025-05",{"name":171,"class":172},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV"]